What is Medherant?
Medherant is at the forefront of developing advanced, sustainable transdermal drug delivery patches designed to significantly enhance patient care. The company's innovative solutions are specifically tailored to address critical areas such as women's health, pain management, and central nervous system (CNS) diseases. By leveraging its proprietary TEPI Patch technology, Medherant aims to provide patients with greater convenience, improved confidence, and enhanced comfort in their treatment regimens. The company actively seeks strategic collaborations to further develop and deploy transdermal or topical delivery systems that capitalize on this cutting-edge technology.
How much funding has Medherant raised?
Medherant has raised a total of $17.7M across 6 funding rounds:
Angel/Seed
$1.9M
Multiple Rounds
$9.5M
Corporate Investment
$2.5M
Other Financing Round
$3.8M
Angel/Seed (2016): $1.9M with participation from Mercia Technologies
Series A (2017): $2M led by Mercia Technologies PLC.
Private Equity (2017): $4.8M supported by Mercia Technologies PLC
Angel/Seed (2017): $2.7M featuring Mercia Fund Management and Mercia Technologies PLC.
Corporate Investment (2019): $2.5M backed by Mercia Technologies
Other Financing Round (2023): $3.8M, investors not publicly disclosed
Key Investors in Medherant
Mercia Technologies
Mercia Asset Management provides equity and debt financing to UK businesses with growth ambitions, acting as investment partners from scale-up to exit. They offer venture capital, business loans, and private equity ranging from £100,000 to £10 million to accelerate growth and impact. Their mission is to be the first-choice provider of capital for businesses typically seeking up to £10 million, emphasizing responsible long-term partnerships. Mercia is committed to empowering UK businesses to innovate and grow, supporting founders in turning bold ideas into thriving enterprises.
Mercia Fund Management
Mercia Fund Management Ltd is a company that operates in the Venture Capital & Private Equity industry. It employs 20to49 people and has 5Mto10M of revenue. The company is headquartered in the United Kingdom.
What's next for Medherant?
The recent major strategic investment in Medherant signals a pivotal moment for the company, likely enabling accelerated development and commercialization of its TEPI Patch technology. This capital infusion is expected to fuel expansion into new therapeutic areas and potentially broaden its market reach. Medherant's focus on sustainable drug delivery positions it well within a growing market demand for patient-centric healthcare solutions. Future growth will likely involve strategic partnerships and further clinical validation to solidify its position in the competitive pharmaceutical landscape.
See full Medherant company page
